The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Novel and Conventional Biomarkers for Prediction of Incident Cardiovascular Events in the Community
Open accessAbstract
CONTEXT: Prior studies have demonstrated conflicting results regarding how much information novel biomarkers add to cardiovascular risk assessment. OBJECTIVE: To evaluate the utility of contemporary biomarkers for predicting cardiovascular risk when added to conventional risk factors. DESIGN, SETTING, AND PARTICIPANTS: Cohort study of 5067 participants (mean age, 58 years; 60% women) without cardiovascular disease from Malmö, Sweden, who attended a baseline examination between 1991 and 1994. Participants underwent measurement of C-reactive protein (CRP), cystatin C, lipoprotein-associated phospholipase 2, midregional proadrenomedullin (MR-proADM), midregional proatrial natriuretic peptide, and N-terminal pro-B-type natriuretic peptide (N-BNP) and underwent follow-up until 2006 using the Swedish national hospital discharge and cause-of-death registers and the Stroke in Malmö register for first cardiovascular events (myocardial infarction, stroke, coronary death). MAIN OUTCOME MEASURES: Incident cardiovascular and coronary events. RESULTS: During median follow-up of 12.8 years, there were 418 cardiovascular and 230 coronary events. Models with conventional risk factors had C statistics of 0.758 (95% confidence interval [CI], 0.734 to 0.781) and 0.760 (0.730 to 0.789) for cardiovascular and coronary events, respectively. Biomarkers retained in backward-elimination models were CRP and N-BNP for cardiovascular events and MR-proADM and N-BNP for coronary events, which increased the C statistic by 0.007 (P = .04) and 0.009 (P = .08), respectively. The proportion of participants reclassified was modest (8% for cardiovascular risk, 5% for coronary risk). Net reclassification improvement was nonsignificant for cardiovascular events (0.0%; 95% CI, -4.3% to 4.3%) and coronary events (4.7%; 95% CI, -0.76% to 10.1%). Greater improvements were observed in analyses restricted to intermediate-risk individuals (cardiovascular events: 7.4%; 95% CI, 0.7% to 14.1%; P = .03; coronary events: 14.6%; 95% CI, 5.0% to 24.2%; P = .003). However, correct reclassification was almost entirely confined to down-classification of individuals without events rather than up-classification of those with events. CONCLUSIONS: Selected biomarkers may be used to predict future cardiovascular events, but the gains over conventional risk factors are minimal. Risk classification improved in intermediate-risk individuals, mainly through the identification of those unlikely to develop events.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Pencina, M. J., D' Agostino, R. B., D' Agostino, R. B., & Vasan, R. S. (2008) · Statistics in Medicine · doi:10.1002/sim.2929 · Cited by 6,493 · cited 6×
“Furthermore, these reclassifications result in only modest improvements in the overall concordance between risk categories and actual event rates, as measured by the NRI.10 Rather than screening the entire adult population using biomarkers, an alternate strategy would be to focus on those individuals deemed to be at i…”
BackgroundMethodInfluentialSelf-citationDowns, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
Use and Misuse of the Receiver Operating Characteristic Curve in Risk Prediction
Cook, N. R. (2007) · Circulation · doi:10.1161/circulationaha.106.672402 · Cited by 2,112
Ridker, P. M., Buring, J. E., Rifai, N., & Cook, N. R. (2007) · JAMA · doi:10.1001/jama.297.6.611 · Cited by 1,814
Prevalence of Conventional Risk Factors in Patients With Coronary Heart Disease
Khot, U. N. (2003) · JAMA · doi:10.1001/jama.290.7.898 · Cited by 1,494
Pencina, M. J., & D'Agostino, R. B. (2004) · Statistics in Medicine · doi:10.1002/sim.1802 · Cited by 1,444
Multiple Biomarkers for the Prediction of First Major Cardiovascular Events and Death
Wang, T. J., Gona, P., Larson, M. G., Tofler, G. H., Levy, D., Newton-Cheh, C., Jacques, P. F., Rifai, N., Selhub, J., Robins, S. J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055373 · Cited by 1,343
Greenland, P. (2008) · Statistics in Medicine · doi:10.1002/sim.2976 · Cited by 1,300
Pepe, M. S. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh101 · Cited by 1,276
Cystatin C and the Risk of Death and Cardiovascular Events among Elderly Persons
Shlipak, M. G., Sarnak, M. J., Katz, R., Fried, L. F., Seliger, S. L., Newman, A. B., Siscovick, D. S., & Stehman-Breen, C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043161 · Cited by 1,249
Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations
Vasan, R. S. (2006) · Circulation · doi:10.1161/circulationaha.104.482570 · Cited by 1,212
Use of Multiple Biomarkers to Improve the Prediction of Death from Cardiovascular Causes
Zethelius, B., Berglund, L., Sundström, J., Ingelsson, E., Basu, S., Larsson, A., Venge, P., & Ärnlöv, J. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707064 · Cited by 889
Ridker, P. M., Paynter, N. P., Rifai, N., Gaziano, J. M., & Cook, N. R. (2008) · Circulation · doi:10.1161/circulationaha.108.814251 · Cited by 841
Shlipak, M. G., Fried, L. F., Cushman, M., Manolio, T. A., Peterson, D., Stehman-Breen, C., Bleyer, A., Newman, A., Siscovick, D., & Psaty, B. (2005) · JAMA · doi:10.1001/jama.293.14.1737 · Cited by 735
The effect of including C-reactive protein in cardiovascular risk prediction models for women
Cook, N. R., Buring, J. E., & Ridker, P. M. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-1-200607040-00128 · Cited by 504 · cited 1×
“ful information for risk prediction has been the focus of intense scrutiny in the cardiovascular literature.(4,6,32) Conflicting findings have been attributed to a variety of factors.”
BackgroundThe Validity of a Diagnosis of Heart Failure in a Hospital Discharge Register
Ingelsson, E., Ärnlöv, J., Sundström, J., & Lind, L. (2005) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2004.12.007 · Cited by 412
Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay
Morgenthaler, N. G., Struck, J., Alonso, C., & Bergmann, A. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2005.051110 · Cited by 399
The search for new cardiovascular biomarkers
Gerszten, R. E., & Wang, T. J. (2008) · Nature · doi:10.1038/nature06802 · Cited by 358
Folsom, A. R., Chambless, L. E., Ballantyne, C. M., Coresh, J., Heiss, G., Wu, K. K., Boerwinkle, E., Mosley, T. H., Sorlie, P., Diao, G., et al. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.13.1368 · Cited by 358
Evaluation of the Performance of Survival Analysis Models: Discrimination and Calibration Measures
D'Agostino, R. B., & Nam, B.-H. (2003) · Handbook of Statistics · doi:10.1016/s0169-7161(03)23001-7 · Cited by 338
Immunoluminometric Assay for the Midregion of Pro-Atrial Natriuretic Peptide in Human Plasma
Morgenthaler, N. G., Struck, J., Thomas, B., & Bergmann, A. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2003.021204 · Cited by 335
Incident coronary events and case fatality in relation to common carotid intima‐media thickness
ROSVALL, M., JANZON, L., BERGLUND, G., ENGSTRÖM, G., & HEDBLAD, B. (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2005.01485.x · Cited by 275
Blankenberg, S., McQueen, M. J., Smieja, M., Pogue, J., Balion, C., Lonn, E., Rupprecht, H. J., Bickel, C., Tiret, L., Cambien, F., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.590927 · Cited by 256
A national record linkage to study acute myocardial infarction incidence and case fatality in Sweden
Hammar, N., Alfredsson, L., Rosen, M., Spetz, C.-L., Kahan, T., & Ysberg, A.-S. (2001) · International Journal of Epidemiology · doi:10.1093/ije/30.suppl_1.s30 · Cited by 252
Assessing the Value of Risk Predictions by Using Risk Stratification Tables
Janes, H., Pepe, M. S., & Gu, W. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-10-200811180-00009 · Cited by 249
Gegenhuber, A., Struck, J., Dieplinger, B., Poelz, W., Pacher, R., Morgenthaler, N. G., Bergmann, A., Haltmayer, M., & Mueller, T. (2007) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.09.004 · Cited by 228
Incidence of stroke is related to carotid IMT even in the absence of plaque
Rosvall, M., Janzon, L., Berglund, G., Engström, G., & Hedblad, B. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.10.015 · Cited by 211
Mohler, E. R., Ballantyne, C. M., Davidson, M. H., Hanefeld, M., Ruilope, L. M., Johnson, J. L., & Zalewski, A. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.11.079 · Cited by 209
Prognostic Value of Midregional Pro-Adrenomedullin in Patients With Acute Myocardial Infarction
Khan, S. Q., O’Brien, R. J., Struck, J., Quinn, P., Morgenthaler, N., Squire, I., Davies, J., Bergmann, A., & Ng, L. L. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.12.038 · Cited by 168
Garza, C. A., Montori, V. M., McConnell, J. P., Somers, V. K., Kullo, I. J., & Lopez-Jimenez, F. (2007) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60992-0 · Cited by 159
Engström, G., Jerntorp, I., Pessah-Rasmussen, H., Hedblad, B., Berglund, G. L., & Janzon, L. (2001) · Stroke · doi:10.1161/01.str.32.5.1098 · Cited by 156
Persson, M., Hedblad, B., Nelson, J. J., & Berglund, G. L. (2007) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.142679 · Cited by 152
Gersh, B. J. (2008) · Yearbook of Medicine · doi:10.1016/s0084-3873(08)79263-0 · Cited by 138
Corson, M. A., Jones, P. H., & Davidson, M. H. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.04.018 · Cited by 133
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
&NA; (1996) · The Endocrinologist · doi:10.1097/00019616-199605000-00022 · Cited by 124
Khan, S. Q., Dhillon, O. S., Kelly, D., Squire, I. B., Struck, J., Quinn, P. A., Morgenthaler, N. G., Bergmann, A., Davies, J. E., & Ng, L. L. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.01.041 · Cited by 78
Serio, F. D., Ruggieri, V., Varraso, L., Sario, R. D., Mastrorilli, A., & Pansini, N. (2005) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2005.217 · Cited by 49
Multiple Biomarker Panels for Cardiovascular Risk Assessment
de Lemos, J. A., & Lloyd‐Jones, D. M. (2008) · New England Journal of Medicine · doi:10.1056/nejme0801721 · Cited by 41
Gersh, B. J. (2008) · Yearbook of Cardiology · doi:10.1016/s0145-4145(08)04050-1 · Cited by 36
Multiple biomarkers for the prediction of first major cardiovascular events and death
Wang, T. J., Gona, P. N., & Larson, M. G. (2007) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2007.01.008 · Cited by 33
Use of multiple biomarkers to improve the prediction of death from cardiovascular causes
Zethelius, B., Berglund, L., & Sundström, J. (2008) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2008.06.012 · Cited by 28
Algorithms for Assessing Cardiovascular Risk in Women
Daniels, L. B., Ben‐Yehuda, O., & Maisel, A. S. (2007) · JAMA · doi:10.1001/jama.298.2.177-a · Cited by 1
Cited by
Writing Committee Members, Greenland, P., Alpert, J. S., Beller, G. A., Benjamin, E. J., Budoff, M. J., Fayad, Z. A., Foster, E., Hlatky, M. A., Hodgson, J. M., et al. (2010) · Circulation · doi:10.1161/cir.0b013e3182051b4c · Cited by 1,873
Registers of the Swedish total population and their use in medical research
Ludvigsson, J. F., Almqvist, C., Bonamy, A.-K. E., Ljung, R., Michaëlsson, K., Neovius, M., Stephansson, O., & Ye, W. (2016) · European Journal of Epidemiology · doi:10.1007/s10654-016-0117-y · Cited by 1,674
Prognosis Research Strategy (PROGRESS) 3: Prognostic Model Research
Steyerberg, E. W., Moons, K. G. M., van der Windt, D. A., Hayden, J. A., Perel, P., Schroter, S., Riley, R. D., Hemingway, H., Altman, D. G., & for the PROGRESS Group (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001381 · Cited by 1,508
2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults
Greenland, P., Alpert, J. S., Beller, G. A., Benjamin, E. J., Budoff, M. J., Fayad, Z. A., Foster, E., Hlatky, M. A., Hodgson, J. M., Kushner, F. G., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.09.001 · Cited by 1,324
Coronary Artery Calcium Score and Risk Classification for Coronary Heart Disease Prediction
Polonsky, T. S. (2010) · JAMA · doi:10.1001/jama.2010.461 · Cited by 1,119
Metadata
- Authors
- Melander, O.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2009-07-01
- Volume
- 302
- Issue
- 1
- Pages
- 49
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2133593325
- Cited by
- 551
- References
- 48
- FWCI
- 73.19
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.